<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="urn:hl7-org:v3" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="31e527e0-ce36-e920-e063-6394a90ac827"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use NITROGLYCERIN SUBLINGUAL TABLETS safely and effectively. See full prescribing information for NITROGLYCERIN SUBLINGUAL TABLETS
 <br/>
      <br/>
      <br/>
      <br/>
NITROGLYCERIN sublingual tablets, for oral use
 <br/>
      <br/>
Initial U.S. Approval: 1981
</title>
   <effectiveTime value="20250403"/>
   <setId root="486f53ce-e3c6-48b0-a6ef-9d08cde387e3"/>
   <versionNumber value="4"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id root="1.3.6.1.4.1.519.1" extension="829572556"/>
            <name>REMEDYREPACK INC.</name>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="31e52906-66ec-0c5d-e063-6394a90a7e6e"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20250403"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="70518-2910" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Nitroglycerin</name>
                        <formCode code="C42998" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Nitroglycerin</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <asEquivalentEntity classCode="EQUIV">
                           <code code="C64637" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <definingMaterialKind>
                              <code code="68462-639" codeSystem="2.16.840.1.113883.6.69"/>
                           </definingMaterialKind>
                        </asEquivalentEntity>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="776XM7047L" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CALCIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="M28OL1HH48" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CROSCARMELLOSE SODIUM</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LACTOSE MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EU2PSP0G0W" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SILICA DIMETHYL SILYLATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="0.4"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="G59M7S0WS3" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>NITROGLYCERIN</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="G59M7S0WS3" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>NITROGLYCERIN</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="25" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43172" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE, GLASS"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="70518-2910-0" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20201019"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA206391" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20201019"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="white" xsi:type="CE">
                              <originalText>white to off white</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="4" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48348" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ROUND" xsi:type="CE">
                              <originalText>Flat faced</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">2;C</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38300" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SUBLINGUAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="S1">
               <id root="d437a2bd-6e1d-779d-e053-2995a90ab50f"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>Nitroglycerin sublingual tablets are indicated for the acute relief of an attack or acute prophylaxis of angina pectoris due to coronary artery disease.</paragraph>
               </text>
               <effectiveTime value="20211228"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Nitroglycerin sublingual tablets are nitrate vasodilator indicated for relief of an attack or prophylaxis of angina pectoris due to coronary artery disease. (
         
 
    <linkHtml href="#S1">1</linkHtml>)
        

   </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S2">
               <id root="d437a2bd-6e1e-779d-e053-2995a90ab50f"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <text>
                  <paragraph>Administer one tablet under the tongue or in the buccal pouch at the first sign of an acute anginal attack. Allow tablet to dissolve without swallowing. One additional tablet may be administered every 5 minutes until relief is obtained. No more than three tablets are recommended within a 15-minute period. If the pain persists after a total of 3 tablets in a 15-minute period, or if the pain is different than is typically experienced, seek prompt medical attention.</paragraph>
                  <paragraph>Nitroglycerin sublingual tablets may be used prophylactically 5 to 10 minutes prior to engaging in activities that might precipitate an acute attack.</paragraph>
                  <paragraph>For patients with xerostomia, a small sip of water prior to placing the tablet under the tongue may help maintain mucosal hydration and aid dissolution of the tablet. </paragraph>
                  <paragraph>Administer nitroglycerin sublingual tablets at rest, preferably in the sitting position.</paragraph>
               </text>
               <effectiveTime value="20211228"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>At the onset of an attack, administer one tablet under the tongue or buccal pouch. One additional tablet may be administered every 5 minutes as needed. No more than 3 total tablets are recommended within a 15 minute period. (
          
  
     <linkHtml href="#S2">2</linkHtml>)
         
 
    </item>
                           <item>If chest pain persists after three tablets, seek prompt medical attention. (
          
  
     <linkHtml href="#S2">2</linkHtml>)
         
 
    </item>
                           <item>May be used prophylactically 5 to 10 minutes prior to engaging in activities that might precipitate an acute attack. (
          
  
     <linkHtml href="#S2">2</linkHtml>)
         
 
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S3">
               <id root="d437a2bd-6e1f-779d-e053-2995a90ab50f"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>Nitroglycerin Sublingual Tablets, USP are supplied as white to off-white, round, flat-faced tablets in three strengths: </paragraph>
                  <list listType="unordered">
                     <item>0.3 mg (Debossed with “1” on one side and “C” on the other)
       </item>
                     <item>0.4 mg (Debossed with “2” on one side and “C” on the other)
       </item>
                     <item>0.6 mg (Debossed with “3” on one side and “C” on the other)
       </item>
                  </list>
               </text>
               <effectiveTime value="20211228"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Sublingual tablets, 0.3 mg; 0.4 mg; 0.6 mg (
         
 
    <linkHtml href="#S3">3</linkHtml>)
        

   </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S4">
               <id root="d437a2bd-6e20-779d-e053-2995a90ab50f"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <effectiveTime value="20211228"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>Use of phosphodiesterase type 5 (PDE-5) inhibitors, such as avanafil, sildenafil, tadalafil, or vardenafil, or soluble guanylate cyclase (sGC) stimulators. (
          
  
     <linkHtml href="#S4.1">4.1</linkHtml>, 
          
  
     <linkHtml href="#S7.1">7.1</linkHtml>)
         
 
    </item>
                           <item>Severe anemia (
          
  
     <linkHtml href="#S4.2">4.2</linkHtml>)
         
 
    </item>
                           <item>Increased intracranial pressure (
          
  
     <linkHtml href="#S4.3">4.3</linkHtml>)
         
 
    </item>
                           <item>Hypersensitivity to nitroglycerin sublingual tablets or to other nitrates or nitrites or any excipient (
          
  
     <linkHtml href="#S4.4">4.4</linkHtml>)
         
 
    </item>
                           <item>Circulatory failure and shock (
          
  
     <linkHtml href="#S4.5">4.5</linkHtml>)
         
 
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S4.1">
                     <id root="d437a2bd-6e21-779d-e053-2995a90ab50f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>4.1 PDE-5-Inhibitors and sGC-Stimulators</title>
                     <text>
                        <paragraph>Do not use nitroglycerin sublingual tablets in patients who are taking PDE-5 Inhibitors, such as avanafil, sildenafil, tadalafil, vardenafil hydrochloride. Concomitant use can cause severe hypotension, syncope, or myocardial ischemia 
         
 
  <content styleCode="italics">[see 
          
  
   <linkHtml href="#S7.1">Drug Interactions (7.1)</linkHtml>].
         
 
  </content>
                        </paragraph>
                        <paragraph>Do not use nitroglycerin sublingual tablets in patients who are taking the soluble guanylate cyclase stimulators, such as riociguat. Concomitant use can cause hypotension.</paragraph>
                     </text>
                     <effectiveTime value="20211228"/>
                  </section>
               </component>
               <component>
                  <section ID="S4.2">
                     <id root="d437a2bd-6e22-779d-e053-2995a90ab50f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>4.2 Severe Anemia</title>
                     <text>
                        <paragraph>Nitroglycerin sublingual tablets are contraindicated in patients with severe anemia (large doses of nitroglycerin may cause oxidation of hemoglobin to methemoglobin and could exacerbate anemia).</paragraph>
                     </text>
                     <effectiveTime value="20211228"/>
                  </section>
               </component>
               <component>
                  <section ID="S4.3">
                     <id root="d437a2bd-6e23-779d-e053-2995a90ab50f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>4.3 Increased Intracranial Pressure</title>
                     <text>
                        <paragraph>Nitroglycerin sublingual tablets may precipitate or aggravate increased intracranial pressure and thus should not be used in patients with possible increased intracranial pressure (e.g., cerebral hemorrhage or traumatic brain injury).</paragraph>
                     </text>
                     <effectiveTime value="20211228"/>
                  </section>
               </component>
               <component>
                  <section ID="S4.4">
                     <id root="d437a2bd-6e24-779d-e053-2995a90ab50f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>4.4 Hypersensitivity</title>
                     <text>
                        <paragraph>Nitroglycerin sublingual tablets are contraindicated in patients who are allergic to nitroglycerin, other nitrates or nitrites or any excipient.</paragraph>
                     </text>
                     <effectiveTime value="20211228"/>
                  </section>
               </component>
               <component>
                  <section ID="S4.5">
                     <id root="d437a2bd-6e25-779d-e053-2995a90ab50f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>4.5 Circulatory Failure and Shock</title>
                     <text>
                        <paragraph>Nitroglycerin sublingual tablets are contraindicated in patients with acute circulatory failure or shock.</paragraph>
                     </text>
                     <effectiveTime value="20211228"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S5">
               <id root="d437a2bd-6e26-779d-e053-2995a90ab50f"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20211228"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>Tolerance: Excessive use may lead to tolerance. (
          
  
     <linkHtml href="#S5.1">5.1</linkHtml>)
         
 
    </item>
                           <item>Hypotension: Severe hypotension may occur. (
          
  
     <linkHtml href="#S5.2">5.2</linkHtml>)
         
 
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S5.1">
                     <id root="d437a2bd-6e27-779d-e053-2995a90ab50f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Tolerance</title>
                     <text>
                        <paragraph>Excessive use may lead to the development of tolerance. Only the smallest dose required for effective relief of the acute angina attack should be used. A decrease in therapeutic effect of sublingual nitroglycerin may result from use of long-acting nitrates.</paragraph>
                     </text>
                     <effectiveTime value="20211228"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.2">
                     <id root="d437a2bd-6e28-779d-e053-2995a90ab50f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 Hypotension</title>
                     <text>
                        <paragraph>Severe hypotension, particularly with upright posture, may occur with small doses of nitroglycerin particularly in patients with constrictive pericarditis, aortic or mitral stenosis, patients who may be volume-depleted, or are already hypotensive. Hypotension induced by nitroglycerin may be accompanied by paradoxical bradycardia and increased angina pectoris. Symptoms of severe hypotension (nausea, vomiting, weakness, pallor, perspiration and collapse/syncope) may occur even with therapeutic doses.</paragraph>
                     </text>
                     <effectiveTime value="20211228"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.3">
                     <id root="d437a2bd-6e29-779d-e053-2995a90ab50f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3 Hypertrophic Obstructive Cardiomyopathy</title>
                     <text>
                        <paragraph>Nitrate therapy may aggravate the angina caused by hypertrophic cardiomyopathy.</paragraph>
                     </text>
                     <effectiveTime value="20211228"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.4">
                     <id root="d437a2bd-6e2a-779d-e053-2995a90ab50f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4 Headache</title>
                     <text>
                        <paragraph>Nitroglycerin produces dose-related headaches, especially at the start of nitroglycerin therapy, which may be severe and persist but usually subside with continued use.</paragraph>
                     </text>
                     <effectiveTime value="20211228"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S6">
               <id root="d437a2bd-6e2b-779d-e053-2995a90ab50f"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following adverse reactions are discussed in more detail elsewhere in the label:</paragraph>
                  <list listType="unordered">
                     <item>Hypotension 
        
  
   <content styleCode="italics">[see 
         
   
    <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]
        
  
   </content>
                     </item>
                     <item>Headache 
        
  
   <content styleCode="italics">[see 
         
   
    <linkHtml href="#S5.4">Warnings and Precautions (5.4)</linkHtml>]
        
  
   </content>
                     </item>
                     <item>Hypersensitivity 
        
  
   <content styleCode="italics">[see 
         
   
    <linkHtml href="#S4.4">Contraindications (4.4)</linkHtml>]
        
  
   </content>
                     </item>
                  </list>
                  <paragraph>Vertigo, dizziness, weakness, palpitation, and other manifestations of postural hypotension may develop occasionally, particularly in erect, immobile patients. Marked sensitivity to the hypotensive effects of nitrates (manifested by nausea, vomiting, weakness, diaphoresis, pallor, and collapse) may occur at therapeutic doses. Syncope due to nitrate vasodilatation has been reported.</paragraph>
                  <paragraph>Flushing, drug rash, and exfoliative dermatitis have been reported in patients receiving nitrate therapy.</paragraph>
               </text>
               <effectiveTime value="20211228"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Most common adverse reactions occurring at a frequency greater than 2% are headache, dizziness and paresthesia. (
         
 
    <linkHtml href="#S6">6</linkHtml>)
        

   </paragraph>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Glenmark Pharmaceuticals Inc., USA at 1 (888) 721-7115 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S7">
               <id root="d437a2bd-6e2c-779d-e053-2995a90ab50f"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <effectiveTime value="20211228"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Ergotamine: increased bioavailability of ergotamine. Avoid concomitant use. (
         
 
    <linkHtml href="#S7.2">7.2</linkHtml>)
        

   </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S7.1">
                     <id root="d437a2bd-6e2d-779d-e053-2995a90ab50f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.1 PDE-5-Inhibitors and sGC-Stimulators</title>
                     <text>
                        <paragraph>Nitroglycerin sublingual tablets are contraindicated in patients who are using a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE-5). PDE-5-Inhibitors such as avanafil, sildenafil, vardenafil, and tadalafil have been shown to potentiate the hypotensive effects of organic nitrates.</paragraph>
                        <paragraph>Nitroglycerin sublingual tablets are contraindicated in patients who are taking soluble guanylate cyclase (sGC) stimulators. Concomitant use can cause hypotension.</paragraph>
                        <paragraph>The time course and dose dependence of these interactions have not been studied, and use within a few days of one another is not recommended. Appropriate supportive care for the severe hypotension has not been studied, but it seems reasonable to treat this as a nitrate overdose, with elevation of the extremities and with central volume expansion.</paragraph>
                     </text>
                     <effectiveTime value="20211228"/>
                  </section>
               </component>
               <component>
                  <section ID="S7.2">
                     <id root="d437a2bd-6e2e-779d-e053-2995a90ab50f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.2 Ergotamine</title>
                     <text>
                        <paragraph>Oral administration of nitroglycerin markedly decreases the first-pass metabolism of dihydroergotamine and subsequently increases its oral bioavailability. Ergotamine is known to precipitate angina pectoris. Therefore, patients receiving sublingual nitroglycerin should avoid ergotamine and related drugs or be monitored for symptoms of ergotism if this is not possible.</paragraph>
                     </text>
                     <effectiveTime value="20211228"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S8">
               <id root="d437a2bd-6e2f-779d-e053-2995a90ab50f"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20211228"/>
               <component>
                  <section ID="S8.1">
                     <id root="d437a2bd-6e30-779d-e053-2995a90ab50f"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <effectiveTime value="20211228"/>
                     <component>
                        <section ID="ID_e87632e1-307c-426d-ae66-603feff002eb">
                           <id root="d437a2bd-6e31-779d-e053-2995a90ab50f"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>Limited published data on the use of nitroglycerin are insufficient to determine a drug associated risk of major birth defects or miscarriage. In animal reproduction studies, there were no adverse developmental effects when nitroglycerin was administered intravenously to rabbits or intraperitoneally to rats during organogenesis at doses greater than 64-times the human dose 
           
 
  <content styleCode="italics">[see 
            
  
   <linkHtml href="#_Ref">Data</linkHtml>]
           
 
  </content>.
          

 </paragraph>
                              <paragraph>The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.</paragraph>
                           </text>
                           <effectiveTime value="20211228"/>
                        </section>
                     </component>
                     <component>
                        <section ID="data">
                           <id root="d437a2bd-6e32-779d-e053-2995a90ab50f"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Data</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20211228"/>
                           <component>
                              <section ID="ID_558f56d7-b4a9-4aa7-9a3d-c3b6a5aac3cc">
                                 <id root="d437a2bd-6e33-779d-e053-2995a90ab50f"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Animal Data</content>
                                    </paragraph>
                                    <paragraph>No embryotoxic or postnatal development effects were observed with transdermal application in pregnant rabbits and rats at doses up to 80 and 240 mg/kg/day, respectively, at intraperitoneal doses in pregnant rats up to 20 mg/kg/day from gestation day 7 to 17, and at intravenous doses in pregnant rabbits up to 4 mg/kg/day from gestation day 6 to 18.</paragraph>
                                 </text>
                                 <effectiveTime value="20211228"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.2">
                     <id root="d437a2bd-6e34-779d-e053-2995a90ab50f"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation</title>
                     <effectiveTime value="20211228"/>
                     <component>
                        <section ID="ID_b1dbe139-cd72-4556-a67d-1adf5dce14e5">
                           <id root="d437a2bd-6e35-779d-e053-2995a90ab50f"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>Sublingual nitroglycerin has not been studied in lactating women. It is not known if nitroglycerin is present in human milk or if nitroglycerin has effects on milk production. </paragraph>
                           </text>
                           <effectiveTime value="20211228"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.4">
                     <id root="d437a2bd-6e36-779d-e053-2995a90ab50f"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>The safety and effectiveness of nitroglycerin in pediatric patients have not been established.</paragraph>
                     </text>
                     <effectiveTime value="20211228"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.5">
                     <id root="d437a2bd-6e37-779d-e053-2995a90ab50f"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>Clinical studies of nitroglycerin sublingual tablets did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.</paragraph>
                     </text>
                     <effectiveTime value="20211228"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S10">
               <id root="d437a2bd-6e38-779d-e053-2995a90ab50f"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <effectiveTime value="20211228"/>
               <component>
                  <section ID="S10.1">
                     <id root="d437a2bd-6e39-779d-e053-2995a90ab50f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>10.1 Signs and Symptoms, Methemoglobinemia</title>
                     <text>
                        <paragraph>Nitrate overdosage may result in: severe hypotension, persistent throbbing headache, vertigo, palpitation, visual disturbance, flushing and perspiring skin (later becoming cold and cyanotic), nausea and vomiting (possibly with colic and even bloody diarrhea), syncope (especially in the upright posture), methemoglobinemia with cyanosis and anorexia, initial hyperpnea, dyspnea and slow breathing, slow pulse (dicrotic and intermittent), heart block, increased intracranial pressure with cerebral symptoms of confusion and moderate fever, paralysis and coma followed by clonic convulsions, and possibly death due to circulatory collapse.</paragraph>
                        <paragraph>Case reports of clinically significant methemoglobinemia are rare at conventional doses of organic nitrates. The formation of methemoglobin is dose-related and in the case of genetic abnormalities of hemoglobin that favor methemoglobin formation, even conventional doses of organic nitrates could produce harmful concentrations of methemoglobin.</paragraph>
                     </text>
                     <effectiveTime value="20211228"/>
                  </section>
               </component>
               <component>
                  <section ID="S10.2">
                     <id root="d437a2bd-6e3a-779d-e053-2995a90ab50f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>10.2 Treatment of Overdosage</title>
                     <text>
                        <paragraph>As hypotension associated with nitroglycerin overdose is the result of venodilatation and arterial hypovolemia, prudent therapy in this situation should be directed toward increase in central fluid volume. No specific antagonist to the vasodilator effects of nitroglycerin is known. Keep the patient recumbent in a shock position and comfortably warm. Passive movement of the extremities may aid venous return. Intravenous infusion of normal saline or similar fluid may also be necessary. Administer oxygen and artificial ventilation, if necessary. If methemoglobinemia is present, administration of methylene blue (1% solution), 1 to 2 mg per kilogram of body weight intravenously, may be required unless the patient is known to have G-6-PD deficiency. If an excessive quantity of nitroglycerin has been recently swallowed gastric lavage may be of use.</paragraph>
                        <paragraph>As epinephrine is ineffective in reversing the severe hypotensive events associated with overdosage, it is not recommended for resuscitation.</paragraph>
                     </text>
                     <effectiveTime value="20211228"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S11">
               <id root="d45faab1-5855-e92f-e053-2995a90a101e"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>Nitroglycerin Sublingual Tablets, USP are stabilized sublingual compressed nitroglycerin tablet that contains 0.3 mg, 0.4 mg, or 0.6 mg nitroglycerin; as well as calcium stearate, croscarmellose sodium, silica dimethyl silylate and lactose monohydrate.</paragraph>
                  <paragraph>Nitroglycerin, an organic nitrate, is a vasodilating agent. The chemical name for nitroglycerin is 1, 2, 3 propanetriol trinitrate and the</paragraph>
                  <paragraph>Molecular weight: 227.09 g/mol</paragraph>
               </text>
               <effectiveTime value="20211228"/>
            </section>
         </component>
         <component>
            <section ID="S12">
               <id root="d437a2bd-6e3c-779d-e053-2995a90ab50f"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20211228"/>
               <component>
                  <section ID="S12.1">
                     <id root="d437a2bd-6e3d-779d-e053-2995a90ab50f"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>Nitroglycerin forms free radical nitric oxide (NO) which activates guanylate cyclase, resulting in an increase of guanosine 3'5' monophosphate (cyclic GMP) in smooth muscle and other tissues. These events lead to dephosphorylation of myosin light chains, which regulate the contractile state in smooth muscle, and result in vasodilatation.</paragraph>
                     </text>
                     <effectiveTime value="20211228"/>
                  </section>
               </component>
               <component>
                  <section ID="S12.2">
                     <id root="d437a2bd-6e3e-779d-e053-2995a90ab50f"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <text>
                        <paragraph>The principal pharmacological action of nitroglycerin is relaxation of vascular smooth muscle. Although venous effects predominate, nitroglycerin produces, in a dose-related manner, dilation of both arterial and venous beds. Dilation of postcapillary vessels, including large veins, promotes peripheral pooling of blood, decreases venous return to the heart, and reduces left ventricular end-diastolic pressure (preload). </paragraph>
                        <paragraph>Nitroglycerin also produces arteriolar relaxation, thereby reducing peripheral vascular resistance and arterial pressure (afterload), and dilates large epicardial coronary arteries; however, the extent to which this latter effect contributes to the relief of exertional angina is unclear.</paragraph>
                        <paragraph>Therapeutic doses of nitroglycerin may reduce systolic, diastolic, and mean arterial blood pressure. Effective coronary perfusion pressure is usually maintained, but can be compromised if blood pressure falls excessively, or increased heart rate decreases diastolic filling time.</paragraph>
                        <paragraph>Elevated central venous and pulmonary capillary wedge pressures, and pulmonary and systemic vascular resistance are also reduced by nitroglycerin therapy. Heart rate is usually slightly increased, presumably due to a compensatory response to the fall in blood pressure. Cardiac index may be increased, decreased, or unchanged. Myocardial oxygen consumption or demand (as measured by the pressure-rate product, tension-time index, and stroke-work index) is decreased and a more favorable supply-demand ratio can be achieved. Patients with elevated left ventricular filling pressures and increased systemic vascular resistance in association with a depressed cardiac index are likely to experience an improvement in cardiac index. In contrast, when filling pressures and cardiac index are normal, cardiac index may be slightly reduced following nitroglycerin administration.</paragraph>
                        <paragraph>Consistent with the symptomatic relief of angina, digital plethysmography indicates that onset of the vasodilatory effect occurs approximately 1 to 3 minutes after sublingual nitroglycerin administration and reaches a maximum by 5 minutes postdose. Effects persist for at least 25 minutes following nitroglycerin administration.</paragraph>
                     </text>
                     <effectiveTime value="20211228"/>
                  </section>
               </component>
               <component>
                  <section ID="S12.3">
                     <id root="d437a2bd-6e3f-779d-e053-2995a90ab50f"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <effectiveTime value="20211228"/>
                     <component>
                        <section ID="ID_17ee42ce-6ac7-4424-b9a0-afe2a4922146">
                           <id root="d437a2bd-6e40-779d-e053-2995a90ab50f"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Absorption</content>
                              </paragraph>
                              <paragraph>Nitroglycerin is rapidly absorbed following sublingual administration of nitroglycerin sublingual tablets. Mean peak nitroglycerin plasma concentrations occur at a mean time of approximately 6 to 7 minutes postdose (Table 1). Maximum plasma nitroglycerin concentrations (C
           
 
  <sub>max</sub>) and area under the plasma concentration-time curves (AUC) increase dose-proportionally following 0.3 to 0.6 mg nitroglycerin. The absolute bioavailability of nitroglycerin from nitroglycerin sublingual tablets is approximately 40% but tends to be variable due to factors influencing drug absorption, such as sublingual hydration and mucosal metabolism.
          

 </paragraph>
                              <table ID="_RefID0EVZAE" width="91.66%">
                                 <caption>Table 1</caption>
                                 <col width="32%"/>
                                 <col width="33%"/>
                                 <col width="34%"/>
                                 <thead>
                                    <tr>
                                       <th align="left" styleCode="Lrule Toprule " valign="top"/>
                                       <th align="center" colspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                          <content styleCode="bold">Mean Nitroglycerin (SD) Values</content>
                                       </th>
                                    </tr>
                                    <tr>
                                       <th align="left" styleCode="Lrule " valign="top"/>
                                       <th align="center" styleCode="Lrule " valign="top">
                                          <content styleCode="bold">2 × 0.3 mg</content>
                                       </th>
                                       <th align="center" styleCode="Rrule Lrule " valign="top">
                                          <content styleCode="bold">1 × 0.6 mg</content>
                                       </th>
                                    </tr>
                                    <tr>
                                       <th align="left" styleCode="Lrule Botrule " valign="middle">
                                          <content styleCode="bold">Parameter</content>
                                       </th>
                                       <th align="center" styleCode="Lrule Botrule " valign="middle">
                                          <content styleCode="bold">Nitroglycerin Sublingual Tablets</content>
                                       </th>
                                       <th align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                          <content styleCode="bold">Nitroglycerin Sublingual Tablets</content>
                                       </th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr>
                                       <td styleCode="Lrule Toprule Botrule " valign="top">
                                          <paragraph>C
               
     
      <sub>max</sub>, ng/mL
              
    
     </paragraph>
                                       </td>
                                       <td align="center" styleCode="Lrule Toprule Botrule " valign="top">
                                          <paragraph>2.3 (1.7)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                          <paragraph>2.1 (1.5)</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Botrule " valign="top">
                                          <paragraph>T
               
     
      <sub>max</sub>, min
              
    
     </paragraph>
                                       </td>
                                       <td align="center" styleCode="Lrule Botrule " valign="top">
                                          <paragraph>6.4 (2.5)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                          <paragraph>7.2 (3.2)</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Botrule " valign="top">
                                          <paragraph>AUC
               
     
      <sub>(0–∞)</sub>, min
              
    
     </paragraph>
                                       </td>
                                       <td align="center" styleCode="Lrule Botrule " valign="top">
                                          <paragraph>14.9 (8.2)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                          <paragraph>14.9 (11.4)</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Botrule Lrule " valign="top">
                                          <paragraph>t
               
     
      <sub>½</sub>, min
              
    
     </paragraph>
                                       </td>
                                       <td align="center" styleCode="Botrule Lrule " valign="top">
                                          <paragraph>2.8 (1.1)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Botrule Lrule " valign="top">
                                          <paragraph>2.6 (0.6)</paragraph>
                                       </td>
                                    </tr>
                                 </tbody>
                              </table>
                           </text>
                           <effectiveTime value="20211228"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_ec97300c-d955-411d-ba7a-8518391ddc88">
                           <id root="d437a2bd-6e41-779d-e053-2995a90ab50f"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Distribution</content>
                              </paragraph>
                              <paragraph>The volume of distribution (V
           
 
  <sub>Area</sub>) of nitroglycerin following intravenous administration is 3.3 L/kg. At plasma concentrations between 50 and 500 ng/mL, the binding of nitroglycerin to plasma proteins is approximately 60%, while that of 1,2- and 1,3-dinitroglycerin is 60% and 30%, respectively.
          

 </paragraph>
                           </text>
                           <effectiveTime value="20211228"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_7a7746fc-6804-4081-aa25-a89779e74f8f">
                           <id root="d437a2bd-6e42-779d-e053-2995a90ab50f"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Metabolism</content>
                              </paragraph>
                              <paragraph>A liver reductase enzyme is of primary importance in the metabolism of nitroglycerin to glycerol di- and mononitrate metabolites and ultimately to glycerol and organic nitrate. Known sites of extrahepatic metabolism include red blood cells and vascular walls. In addition to nitroglycerin, 2 major metabolites 1,2- and 1,3-dinitroglycerin, are found in plasma. Mean peak 1,2- and 1,3-dinitroglycerin plasma concentrations occur at approximately 15 minutes postdose. The elimination half-life of 1,2- and 1,3-dinitroglycerin is 36 and 32 minutes, respectively. The 1,2- and 1,3-dinitroglycerin metabolites have been reported to possess approximately 2% and 10%, respectively, of the pharmacological activity of nitroglycerin. Higher plasma concentrations of the dinitro metabolites, along with their nearly 10-fold longer elimination half-lives, may contribute significantly to the duration of pharmacologic effect. Glycerol mononitrate metabolites of nitroglycerin are biologically inactive.</paragraph>
                           </text>
                           <effectiveTime value="20211228"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_2c9e349c-eabe-41ba-a89d-75dce58433f5">
                           <id root="d437a2bd-6e43-779d-e053-2995a90ab50f"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Elimination</content>
                              </paragraph>
                              <paragraph>Nitroglycerin plasma concentrations decrease rapidly, with a mean elimination half-life of 2 to 3 minutes. Half-life values range from 1.5 to 7.5 minutes. Clearance (13.6 L/min) greatly exceeds hepatic blood flow. Metabolism is the primary route of drug elimination.</paragraph>
                           </text>
                           <effectiveTime value="20211228"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_44c1b65c-9347-4350-9f9d-e84bc8915908">
                           <id root="d437a2bd-6e44-779d-e053-2995a90ab50f"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Drug interactions</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20211228"/>
                           <component>
                              <section ID="ID_24e0b4a7-05dd-4cff-ba87-d39b62828b66">
                                 <id root="d437a2bd-6e45-779d-e053-2995a90ab50f"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Aspirin:</content> Coadministration of nitroglycerin with high dose aspirin (1000 mg) results in increased exposure to nitroglycerin. The vasodilatory and hemodynamic effects of nitroglycerin may be enhanced by concomitant administration of nitroglycerin with high dose aspirin.
            

 </paragraph>
                                 </text>
                                 <effectiveTime value="20211228"/>
                              </section>
                           </component>
                           <component>
                              <section ID="ID_8a28d92d-57e0-4fe9-96b8-3842de87c2b4">
                                 <id root="d437a2bd-6e46-779d-e053-2995a90ab50f"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Tissue-type plasminogen activator (t-PA)</content>: Concomitant administration of t-PA and intravenous nitroglycerin has been shown to reduce plasma levels of t-PA and its thrombolytic effect.
            

 </paragraph>
                                 </text>
                                 <effectiveTime value="20211228"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S13">
               <id root="d437a2bd-6e47-779d-e053-2995a90ab50f"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20211228"/>
               <component>
                  <section ID="S13.1">
                     <id root="d437a2bd-6e48-779d-e053-2995a90ab50f"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>Animal carcinogenesis studies with sublingually administered nitroglycerin have not been performed.</paragraph>
                        <paragraph>Carcinogenicity potential of nitroglycerin was evaluated in rats receiving up to 434 mg/kg/day of dietary nitroglycerin for 2 years. Rats developed dose-related fibrotic and neoplastic changes in liver, including carcinomas, and interstitial cell tumors in testes. At high dose, the incidences of hepatocellular carcinomas in males was 48% and in females was 33%, compared to 0% in untreated controls. Incidences of testicular tumors were 52% vs. 8% in controls. Lifetime dietary administration of up to 1058 mg/kg/day of nitroglycerin was not tumorigenic in mice.</paragraph>
                        <paragraph>Nitroglycerin was mutagenic in Ames tests performed in 2 different laboratories. Nevertheless, there was no evidence of mutagenicity in an 
         
 
  <content styleCode="italics">in vivo</content> dominant lethal assay with male rats treated with doses up to about 363 mg/kg/day, PO, or in ex vivo cytogenetic tests in rat and dog cells.
        

 </paragraph>
                        <paragraph>In a 3-generation reproduction study, rats received dietary nitroglycerin at doses up to about 434 mg/kg/day for 6 months prior to mating of the F0 generation, with treatment continuing through successive F1 and F2 generations. The high dose was associated with decreased feed intake and body weight gain in both sexes at all matings. No specific effect on the fertility of the F0 generation was seen. Infertility noted in subsequent generations, however, was attributed to increased interstitial cell tissue and aspermatogenesis in the high-dose males. In this 3-generation study, there was no clear evidence of teratogenicity.</paragraph>
                     </text>
                     <effectiveTime value="20211228"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S16">
               <id root="d437a2bd-6e49-779d-e053-2995a90ab50f"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph>Nitroglycerin Sublingual Tablets, USP are supplied as white to off white, round, flat-faced tablets in 0.4 mg Debossed with “2” on one side and “C” on the other</paragraph>
                  <paragraph>NDC: 70518-2910-00</paragraph>
                  <paragraph>PACKAGING: 1 in 1 CARTON, 25 in 1 BOTTLE, GLASS</paragraph>
                  <paragraph/>
                  <paragraph>Store at 20°C to 25°C (68°F to 77°F) [see USP Controlled Room Temperature]. Nitroglycerin should be kept in the original glass container and must be tightly capped after each use to prevent loss of tablet potency.</paragraph>
                  <paragraph/>
                  <paragraph>Repackaged and Distributed By:</paragraph>
                  <paragraph>Remedy Repack, Inc.</paragraph>
                  <paragraph>625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762</paragraph>
                  <paragraph/>
               </text>
               <effectiveTime value="20211228"/>
            </section>
         </component>
         <component>
            <section ID="S17">
               <id root="d437a2bd-6e4a-779d-e053-2995a90ab50f"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>Advise the patient to read the FDA-approved patient labeling (Patient Information).</paragraph>
                  <paragraph>This product's label may have been updated. For full prescribing information, please visit 
       
 
  <linkHtml href="http://www.glenmarkpharma-us.com">www.glenmarkpharma-us.com</linkHtml>.
      

 </paragraph>
                  <paragraph>Repackaged By / Distributed By: RemedyRepack Inc.</paragraph>
                  <paragraph>625 Kolter Drive, Indiana, PA 15701</paragraph>
                  <paragraph>(724) 465-8762</paragraph>
               </text>
               <effectiveTime value="20211228"/>
            </section>
         </component>
         <component>
            <section ID="ID_b5ebbb4d-d38f-4134-8463-2b0acfb7b32c">
               <id root="d437aa02-5380-369e-e053-2a95a90aba51"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <paragraph>Repackaged and Distributed By:</paragraph>
                  <paragraph>Remedy Repack, Inc.</paragraph>
                  <paragraph>625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762</paragraph>
               </text>
               <effectiveTime value="20211228"/>
            </section>
         </component>
         <component>
            <section ID="ID_4d44e286-9b0d-4eab-9bec-95b77fa76715">
               <id root="d437aa02-5381-369e-e053-2a95a90aba51"/>
               <code code="42230-3" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PATIENT PACKAGE INSERT SECTION"/>
               <title>Patient Information</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Nitroglycerin (nahy- 
   <content styleCode="italics">truh</content>-glis-er-in) 
  </content>
                     <br/>
                     <br/>
                     <content styleCode="bold">Sublingual Tablets, USP</content>
                  </paragraph>
                  <paragraph>Read this information carefully before you start 
  <content styleCode="bold">nitroglycerin sublingual tablets</content> and each time you refill your prescription. There may be new information. This information does not replace talking with your doctor. If you have any questions about 
  <content styleCode="bold">nitroglycerin sublingual tablets</content>, ask your doctor. Your doctor will know if 
  <content styleCode="bold">nitroglycerin sublingual tablets</content> are right for you.
 </paragraph>
                  <paragraph>
                     <content styleCode="bold">What are Nitroglycerin Sublingual Tablets? </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Nitroglycerin sublingual tablets </content>are type of medicine known as an organic nitrate and is a vasodilating agent. It is used to treat a type of chest pain called angina.
 </paragraph>
                  <paragraph>
                     <content styleCode="bold">What is Angina? </content>
                  </paragraph>
                  <paragraph>Angina is a pain or discomfort that keeps coming back when part of your heart does not get enough blood. Angina feels like a pressing or squeezing pain, usually in your chest under the breastbone. Sometimes you can feel it in your shoulders, arms, neck, jaws, or back. 
  <content styleCode="bold">Nitroglycerin sublingual tablets</content> can relieve this pain.
 </paragraph>
                  <paragraph>
                     <content styleCode="bold">Who should not use Nitroglycerin Sublingual Tablets?</content>
                  </paragraph>
                  <paragraph>Do not use 
  <content styleCode="bold">nitroglycerin sublingual tablets</content> if you are allergic to organic nitrates (like the active ingredient in 
  <content styleCode="bold">nitroglycerin</content>).
 </paragraph>
                  <paragraph>You should not take 
  <content styleCode="bold">nitroglycerin sublingual tablets</content> if you have the following conditions:
 </paragraph>
                  <list listType="unordered">
                     <item>very recent heart attack</item>
                     <item>severe anemia</item>
                     <item>increased pressure in the head</item>
                  </list>
                  <paragraph>Do not take 
  <content styleCode="bold">nitroglycerin sublingual tablets</content> with drugs for erectile dysfunction, like VIAGRA 
  <sup>®</sup> (sildenafil citrate), CIALIS 
  <sup>®</sup> (tadalafil), or LEVITRA 
  <sup>®</sup> (vardenafil hydrochloride), as this may lead to extreme lowering of your blood pressure 
  <content styleCode="italics">.</content>
                  </paragraph>
                  <paragraph>Do not take 
  <content styleCode="bold">nitroglycerin sublingual tablets</content> if you take medicines called guanylate cyclase stimulators which include riociguat, a medicine that treats pulmonary arterial hypertension and chronic-thromboembolic pulmonary hypertension.
 </paragraph>
                  <paragraph>
                     <content styleCode="bold">What should I tell my doctor before taking Nitroglycerin Sublingual Tablets?</content>
                  </paragraph>
                  <paragraph>Before using 
  <content styleCode="bold">nitroglycerin sublingual tablets</content>, tell your doctor if:
 </paragraph>
                  <list listType="unordered">
                     <item>You are taking any medicines that are used to treat angina, heart failure, or an irregular heartbeat.</item>
                     <item>You are taking any medicines that reduce blood pressure.</item>
                     <item>You are taking any diuretics (water pills).</item>
                     <item>You are taking medicines that can cause dry mouth such as tricyclic antidepressants (e.g. amitriptyline, desipramine, doxepin), anticholinergic drugs, or any antimuscarinic drugs (e.g. atropine).</item>
                     <item>You are taking ergotamine or similar drugs for migraine headaches.</item>
                     <item>You are taking aspirin.</item>
                     <item>You are taking any medicines for erectile dysfunction.</item>
                     <item>You are pregnant or plan to become pregnant.</item>
                     <item>You are breastfeeding.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">How should I take Nitroglycerin Sublingual Tablets?</content>
                  </paragraph>
                  <list listType="unordered">
                     <item>Do not chew, crush, or swallow 
   <content styleCode="bold">nitroglycerin sublingual tablets</content>.
  </item>
                     <item>You should sit down when taking 
   <content styleCode="bold">nitroglycerin sublingual tablets</content> and use caution when you stand up. This eliminates the possibility of falling due to lightheadedness or dizziness.
  </item>
                     <item>One tablet should be dissolved under the tongue or in the oral cavity at the first sign of chest pain.</item>
                     <item>The dose may be repeated approximately every 5 minutes, until the chest pain is relieved.</item>
                     <item>If the pain persists after a total of 3 tablets in a 15-minute period, or is different than you typically experience, call your doctor or seek emergency help.</item>
                     <item>
                        <content styleCode="bold">Nitroglycerin sublingual tablets</content> may be used 5 to 10 minutes prior to activities that might cause chest pain.
  </item>
                     <item>You may feel a burning or tingling sensation in your mouth when you take 
   <content styleCode="bold">nitroglycerin sublingual tablets</content>.
  </item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">What should I avoid while taking Nitroglycerin Sublingual Tablets?</content>
                  </paragraph>
                  <list listType="unordered">
                     <item>Do not breastfeed. It is not known if 
   <content styleCode="bold">nitroglycerin</content> will pass through your milk.
  </item>
                     <item>Do not consume alcohol while taking 
   <content styleCode="bold">nitroglycerin sublingual tablets</content>, as this can lower your blood pressure.
  </item>
                     <item>Do not start any new prescription or non-prescription medicines or supplements, unless you check with your doctor first.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">What are the possible side effects of Nitroglycerin Sublingual Tablets?</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Nitroglycerin sublingual tablets</content> may cause the following side effects:
 </paragraph>
                  <list listType="unordered">
                     <item>headache</item>
                     <item>vertigo (a major symptom of balance disorder)</item>
                     <item>dizziness</item>
                     <item>weakness</item>
                     <item>heart palpitations (unusual awareness of the heartbeat)</item>
                     <item>low blood pressure upon rising from a seated position</item>
                     <item>nausea and vomiting</item>
                     <item>sweating</item>
                     <item>paleness</item>
                     <item>fainting</item>
                     <item>flushing (warm or red condition of your skin)</item>
                     <item>other skin reactions that may be severe</item>
                  </list>
                  <paragraph>Tell your doctor if you are concerned about any side effects you experience. These are not all the possible side effects of 
  <content styleCode="bold">nitroglycerin sublingual tablets</content>. For a complete list, ask your doctor or pharmacist.
 </paragraph>
                  <paragraph>
                     <content styleCode="bold">How do I store Nitroglycerin Sublingual Tablets?</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Nitroglycerin sublingual tablets</content> should be kept in the original glass container and tightly capped after each use to prevent loss of tablet potency.
 </paragraph>
                  <paragraph>Store 
  <content styleCode="bold">nitroglycerin sublingual tablets </content>at 20°C to 25°C (68°F to 77°F) [see USP Controlled Room Temperature].
 </paragraph>
                  <paragraph>
                     <content styleCode="bold">General advice about Nitroglycerin Sublingual Tablets</content>
                  </paragraph>
                  <paragraph>Sometimes doctors will prescribe a medicine for a condition that is not included in the patient information leaflets. Only use 
  <content styleCode="bold">nitroglycerin sublingual tablets</content> the way your doctor told you to. Do not give 
  <content styleCode="bold">nitroglycerin sublingual tablets</content> to other people, even if they have the same symptoms you have. They may harm them.
 </paragraph>
                  <paragraph>You can ask your pharmacist or doctor for information about 
  <content styleCode="bold">nitroglycerin sublingual tablets</content>, or you can call Glenmark Pharmaceuticals Inc., USA at 1 (888) 721-7115.
 </paragraph>
                  <paragraph/>
                  <paragraph>Repackaged and Distributed By:</paragraph>
                  <paragraph>Remedy Repack, Inc.</paragraph>
                  <paragraph>625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762</paragraph>
               </text>
               <effectiveTime value="20211228"/>
            </section>
         </component>
         <component>
            <section ID="id_link_d45e3db7-e45f-11af-e053-2a95a90ab07b">
               <id root="d45faadb-3407-426b-e053-2a95a90a835f"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL</title>
               <text>
                  <paragraph>DRUG: Nitroglycerin</paragraph>
                  <paragraph>GENERIC: Nitroglycerin</paragraph>
                  <paragraph>DOSAGE: TABLET</paragraph>
                  <paragraph>ADMINSTRATION: SUBLINGUAL</paragraph>
                  <paragraph>NDC: 70518-2910-0</paragraph>
                  <paragraph>COLOR: white</paragraph>
                  <paragraph>SHAPE: ROUND</paragraph>
                  <paragraph>SCORE: No score</paragraph>
                  <paragraph>SIZE: 4 mm</paragraph>
                  <paragraph>IMPRINT: 2;C</paragraph>
                  <paragraph>PACKAGING: 25 in 1 BOTTLE, GLASS</paragraph>
                  <paragraph>OUTER PACKAGING: 1 in 1 CARTON</paragraph>
                  <paragraph>ACTIVE INGREDIENT(S):</paragraph>
                  <list listType="unordered">
                     <item>NITROGLYCERIN 0.4mg in 1</item>
                  </list>
                  <paragraph>INACTIVE INGREDIENT(S):</paragraph>
                  <list listType="unordered">
                     <item>CALCIUM STEARATE</item>
                     <item>CROSCARMELLOSE SODIUM</item>
                     <item>LACTOSE MONOHYDRATE</item>
                     <item>SILICA DIMETHYL SILYLATE</item>
                  </list>
                  <paragraph>
                     <renderMultiMedia referencedObject="img_d45faab1-5853-e92f-e053-2995a90a101e"/>
                  </paragraph>
                  <paragraph/>
               </text>
               <effectiveTime value="20211228"/>
               <component>
                  <observationMedia ID="img_d45faab1-5853-e92f-e053-2995a90a101e">
                     <text>MM1</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="Nitroglycerin  0.4mg_70518-2910-00.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>